Business Briefing on*
CDMO business for bio-antibody drugs
March 2024

SIIX Corporation*CDMO: Contract Manufacturing and Development Organization

INDEX• Corporate Profile of SIIX Corporation• Corporate Profile of RENZOKU Biologics Inc.
• Entry into the CDMO business for antibody drugs• Introduction of CEO of Renzoku Biologics Inc.

Copyright © 2024 SIIX Corporation All rights reserved.

1

Corporate Profile
Name

Revenue(JPY in billions)

SIIX Corporation

350.0

Type of Industry

Trading of Electric Components & PCBA, EMS

Establishment

July 1, 1992

CapitalJPY 2,144 million

309.7

330.0

300.0
250.0
200.0

150.0
100.0

Location

Osaka Headquarters（Chuo-ku Osaka, Japan)
Tokyo Headquarters（Chiyoda-ku Tokyo, Japan)
Nagoya Sales Dep.（Nagoya, Aichi, Japan)

50.0
0.0
2017

Listed Market

Prime Market, Tokyo Stock Exchange（Ticker Code：7613）# of Employees

Consolidated 11,052, Non-consolidated 214（as of DEC 2023） (JPY in billions)

Network

Overseas 22（10 factories, 12 Offices）
Domestic 2（Headquarters, 1 Factory）(as od DEC 2023）

2019

2020

2021

2022

2023

2024
(Forecast)

Operating Income

14.0

12.2

13.2

12.0

認証取得

ISO9001, ISO14001, ISO27001, IATF16949, ISO13485

10.0

Major Shareholders

Sakata Inx Corp.
Japan Master Trust
SIIX Corp.
Forty-Six
Resona Holdings, Inc.
Sumitomo Mitsui Banking Corporation

6.0

21.45%
8.82%
6.60%
4.37%
4.31%
4.29%

2018

8.0

4.0
2.0
0.0
2017

Copyright © 2024 SIIX Corporation All rights reserved.

2018

2019

2020

2021

2022

2023

2024
(Forecast)2

Corporate Profile of Renzoku Biologics
Company Name
Location

Renzoku Biologics Inc.
Marunouchi Trust Tower 20F, 1-8-3, Marunouchi, Chiyoda-ku, Tokyo, Japan

Representative

Hitoshi Kuboniwa, PhD, CEO

Establishment

August 22, 2023

CapitalJPY 1,195 million

Shareholding

SIIX Corp. 96%

Fiscal Period

December

Main BusinessContract development and manufacturing of antibody drugs, etc.

Copyright © 2024 SIIX Corporation All rights reserved.

3

Entry into the CDMO business for antibody drugs
Background
We organize customers needsaround the world to create business as

Global Business Organizer• In researching the healthcare-related market, we
noticed that there is a strong unmet need in thebiopharmaceutical field.
• In the pharmaceutical industry, as in the electronics
industry, there is a horizontal division of labor.
• High affinity of business model

Our Target• "EMS for pharmaceuticals" = Entry into CDMO business (contract manufacturing and development business)• Aiming for social implementation of fully continuous production technology with excellent production scale variability andflexible response to small- and medium-volume, high-mix production.
• Maximize synergies with the antibody drug field by leveraging our expertise in operations management and global expansion
cultivated as an EMS

Operations Management: DX/ICT-enabled data, quantification, visualization,
remoteness, traceability, etc. Expertise in automation and labor saving
Copyright © 2024 SIIX Corporation All rights reserved.

4

Introduction of CEO of Renzoku Biologics Inc.
Chief Executive Officer

Hitoshi Kuboniwa（PhD）
Former Senior Executive Officer, Pharmaceuticals representative,
Managing Executive Officer, General Manager of Pharmaceuticals Division of
Chugai Pharmaceutical Co., Ltd.
D. in Polymer Engineering, Tokyo Institute of Technology
More than 40 years of experience in R&D, business development,biopharmaceutical manufacturing and supply chain management
in major pharmaceutical company
Chair, Steering Committee, Japan Bioindustry Association (JBA)
Chairman, JBA Drug Discovery Modality Infrastructure Research Group

Copyright © 2024 SIIX Corporation All rights reserved.

5

Renzoku Biologics
A Centre of Excellence for Advanced Biomanufacturing

March 2024
©Renzoku Biologics Inc.

Presentation Summary

1

About Biopharmaceuticals

2Biopharmaceutical Manufacturing and CDMOs

3

About Renzoku Biologics

4

CDMO Market Entry Strategy

5

Collaboration with SIIX Corp.

©Renzoku Biologics Inc.

1

1.
©Renzoku Biologics Inc.

About Biopharmaceuticals

バイ オ医薬品と 一般的な医薬品と の違い

Smallバイオ医薬品は、変化に敏感な微生物や動物細胞等を用いて作られる、
molecule drugs & Biopharmaceuticals

非常に大きくて複雑な構造を持つ医薬品であるため、よりシビアなバイ オ医薬品と 一般的な医薬品と の違い
バイオ医薬品は、変化に敏感な微生物や動物細胞等を用いて作られる、Biopharmaceuticals
Smallmolecule drugs
製造工程管理が必要です。
非常に大きくて複雑な構造を持つ医薬品であるため、よりシビアな
バイオ医薬品は、変化に敏感な微生物や動物細胞等を用いて作られる、製造工程管理が必要です。

一般的な医薬品大きさ(分子量)100～大きさ(分子量)Molecularsize
大きさ･複雑さ& Image

製造法
Manufacturing
Quality(イメージ)
Features100～

Antibody

Large, Complex（ten~hundred
thousand)約1万～(ホルモン等)
約10万～(抗体)

大きさ･複雑さ(イメージ)大きさ･複雑さ(イメージ)

化学合成
微生物や細胞の中で合成
化学合成
微生物や細胞の中で合成
Chemically synthesized
Producedusing living cells and microorganisms
製造法
製造法
化学合成
（organic synthetic(イメージ)
chemistry） 微生物や細胞の中で合成（genetic
engineering）
抗体などの
抗体などの
微生物や細胞(イメージ)
遺伝子
微生物や細胞遺伝子
抗体などのPossible to manufacture identical products
Difficultto produce
不安定 completely identical products
生産微生物や細胞
安定遺伝子
at the molecular level (Genericdrugs)
at the 不安定
molecular level(Biosimilars)(微生物や細胞の状態で生産物が変わり
得る
｡)

生産

安定

(微生物や細胞の状態で生産物が変わり 得る ｡)

20～30 2billion
JPY
厚生労働省：バイオシミラーの現状について（平成27年7月23日）
改変
不安定

Development Cost＊

生産

安定
2

Manufacturing Cost＊
2

約1万～(ホルモン等)
約10万～(抗体)
一般的な医薬品約1万～(ホルモン等)
バイオ医薬品 約10万～(抗体)Hormoneprotein100～

Small（Most are less大きさ
than 500）(分子量)(イメージ)

Manufacturing method（Technology）

非常に大きくて複雑な構造を持つ医薬品であるため、よりシビアなバイ オ医薬品
一般的な医薬品
バイ オ医薬品
製造工程管理が必要です。

50～100 billion JPY(微生物や細胞の状態で生産物が変わり得る that｡) of
CAPEX:
3-10 times

厚生労働省：バイオシミラーの現状について（平成27年7月23日） 改変ー

厚生労働省：バイオシミラーの現状について（平成27年7月23日） 改変

small molecule drugs
Quality control: 1.3-1.8 times that ofsmall molecule drugs＊Source: The Japan Biosimilar Association©Renzoku Biologics Inc.

3

History of Pharmaceutical Innovation andEmergence of Biopharmaceuticals
Scientific developments have enabled the creation of innovative drugs.
Genetic recombination,
maturation of
antibody engineering

Application of Genetic
Recombination
Technology

Focus on thefunction of receptors
in the body

1900
©Renzoku Biologics Inc.

Human insulin
Interferon
Antihypertensive

Anti-inflammatory/analgesic drug
Penicillin

Focus on thefunction of enzymes
in the body

H2 Blockers
Peptic ulcer

The first antibiotic.
Saved countless people
from infections!

1960

Cell & Gene
Therapy
Antibody
drugs

The Dawn of Personalized
Medicine/Precision Medicine

Regenerative
medicine

Hyperlipidemia
drugs

Organic Synthesis
Technology and Drug
Screening
Naturally derived
ingredients andtheir derivatives

Development of genome
technology andinformation science

1970

Discovered in Japan.
Adult Disease
Prevention

Emergence ofBiopharmaceuticals

The pharmaceuticalparadigm has changed
dramatically.

Surgery for gastriculcers is no longer
necessary!

1980

1990

Pinpoint Attack on Cancer.
Became a major player inbiopharmaceuticals.

2000

2010

2020
4

Over the past 30 years, Japan has lost its competitive edge in drug discovery.

Slow internationalization and scaling up, slow "bio-shift“,
Lack of quality and quantity of start-ups

6%

Percentage of the Japanese market in the global pharmaceuticalmarket(the only negative growth among the 10 leading countries)

72%

71%
80%

Percentage of "unapproved drugs in Japan" among drugs
approved in the U.S. and Europe (2016-2020)(More than half of the "drugs not approved in Japan (56%)" in the last 10 years have no
information on development in Japan.)

Percentage of "biopharmaceuticals" among the world's top 50
drugs in terms of sales(47 biotech products out of the world's Top 100, of which only 2 are from Japan)

Percentage of "venture/academia-originated" drugs in global
development(In Japan, only 23% of "venture/academia-originated" drugs)

As of YR2021©Renzoku Biologics Inc.

6

A Strong Drug Discovery Ecosystem Supports Japan's Medical Security• Drug Discovery Ecosystem Supports Drug Discovery Capability as a Comprehensive Strength• CMOs/CDMOs are key players in the drug discovery ecosystem◼

Deep understanding of "disease biology”✓◼

Evolution and deepening of "modality"✓◼

◼

Strengthen basic life science and basic medical research

Drug Discovery Ecosysteminnovative pharmaceuticals

Development of multimodality (multimodal) therapy

International standard "platform technology”① Disease biology✓

Quickly create high-quality projects (seeds), and...

research✓

Quickly transform the projects that are created into products.

“Emergent Spaces" for Fostering Innovation:
Conflicts and Fusions✓

Formation of a global bio-community

One of the factors that contributed to the difference between Japanand others in the pandemic situation, where vaccines andtherapeutics had to be delivered quickly to patients, was thedifference in "production capacity" not only in the fields of"disease biology" and "modalities" but also in biopharmaceuticals ingeneral, not just in the vaccine field.
©Renzoku Biologics Inc.

② Treatment
technique

Emergence✓ Basic Life Science Research✓ Basic Medical Research✓ Clinical Medicine Research✓ Genome Data
✓ Medical Data

③ Platform Technology(Technology that contributes toincreased productivity in research,development, and manufacturing)(modality)✓ Next Generation
Antibody✓ Gene/Cell Therapy✓ Nucleic acid medicine✓ Medium Molecules✓ New Modality✓ Next-generation peripheral technologies such as IT, automation, genetic
engineering, protein engineering, antibody engineering, pharmacology,
pharmacokinetics, analysis, production technology, bioprocess development,
and engineering that can dramatically improve "productivity" in the value
chain (research, development, and manufacturing) of pharmaceuticalproducts from seed to market

72.
©Renzoku Biologics Inc.

Biopharmaceutical Manufacturing
and CDMOs

Monoclonal Antibodies (mAbs) are a major part ofthe biopharmaceuticals market
Monoclonal antibodies (mAbs) are artificially
produced proteins/antibodies that can bind to
specific targets in the body, often on cancer cells

Percentage of each "modality" inbiopharmaceuticals currently on the market
or under regulatory review

10%
6%
44%

11%

14%

15%
History of Antibody Drug Development

1975 : Discovery of Hybridoma → Mouse Mab
1985 : Discovery of Phage display → Humanization of Ab
2010-: Advanced Ab engineering→ Bispecific Ab, ADC, small molecule Ab©Renzoku Biologics Inc.

Monoclonal Antibodies

Other Proteins

PeptidesCell and tissue therapies

Gene therapies

Others

Source: BiotechGate, Ginward analysis

9The emergence of biopharmaceuticals created a paradigm shift
in manufacturing
Biologics production process
Small molecule drug
production process

1897 1923

1983

1986

From small molecules to biologics
The advent of genetic modification technology has made it possible forhumans to create complex molecules that previously could only be extracted
from animals, plants and other natural sources©Renzoku Biologics Inc.

Renzoku aims to target“Continuous
Manufacturing”

10CDMOs are playing an increasing role in supporting drug developers
through externalized services
Drivers of Horizontal Division of Labor• Production of biopharmaceuticals requires huge initial investment, technologies and know-how that differ from those of conventional synthetic drugs• As development costs increase dramatically, pharmaceutical companies are actively utilizing external resources (CMOs, CDMOs, CROs) to focus their resources on creating new drugs.
• Ventures play a major role in biopharmaceutical development, but those without financial resources need to outsource production

Pharma <> CDMO
Types of support/partnership

Dev.

Clinical

Comm.

Dev.

Parallel Manufacturing(capacity management)

Dev.

Clinical

Comm.

Dev.

ClinicalComm.

Fully outsourced development& commercial manufacturing(CDMO)©Renzoku Biologics Inc.

Dev.

CDMO

Outsourced
Manufacturing (CMO)

Capacity Management

Comm.

CMO

Outsourced Drug
Development (CRO)

ClinicalCMO/CDMO

CRO

Fully in-house

Drug developers(pharma, biotech, academia, etc.)

Dev.

ClinicalComm.

ClinicalComm.

Clinical

Comm.

11

3. About Renzoku Biologics©Renzoku Biologics Inc.

Renzoku’s Mission & Vision
MISSION

Contribute to human health and medical care around the world
through innovation of biopharmaceutical manufacturing
SHORT AND MEDIUM-TERM VISION
～2026

～2029

Short-term Vision

Medium-term Vision• Build GMP production capacity (50L) to enable
contract manufacturing of investigational drugs.
• Leveraging advanced manufacturing technologies,
including continuous manufacturing, Renzoku haslaid the foundation for CDMO companies to berecognized as Centers of Excellence inbiopharmaceutical manufacturing.

©Renzoku Biologics Inc.

• Build a facility with GMP production capacity (500L)
and facilities to enable commercial production
contracts.
• Expand business domestically and internationally tosecure a revenue base for growth.

14Realize an "advanced biopharmaceutical factory“by integrating technologies through breakthrough innovation

Digitalization

Fully
Continuous
Manufacturing

Cell line
development“Quick & Small" realizedby "Advanced Biopharmaceutical Plant”
Small facilities
with short
set-up time

Automation/ Robotics

Advanced
Biomanufacturing
FactoryStandardization

04

Continuous
biomanufacturinglines and facilities
require lessmanpower tooperateSmall and modular facility
with shortened timelinefrom construction tooperation

Quality by
Design(Processes,
facilities,
equipment, rawmaterials)

Advancedfacility
design©Renzoku Biologics Inc.

Process
Analytic
Technology

01

Low
headcountrequirement

Sustainability
Technology

Target projects withsmall to medium
volumes
Strategically targeting an
underserved market inbiomanufacturing

02

03

Flexible
production plan

Continuous manufacturinglines can accommodatechanges in production
timeline

15

Advanced Biopharmaceutical Plant Delivers Value to Customers“Quick & Small”

Drug developers(pharma, biotech, academia, etc.)• Small facilities（Small footprint)• More easily replication of factory(cloning strategy)• Fast and flexible access toinvestigational drugs and finishedproducts. Shorten time to start
clinical trials and time to market.

• Faster technology transfer

COST• FIH（First In Human),Shorter lead time to market• Reduction of manufacturing costs

OPPORTUNITY• More flexible production scalechanges• Enables management of own
continuous production capacity• Shorter production changeovertime• Easier access to investigational
drugs for venture capitalists andacademia, making it easier tocross the "valley of death”• Low personnel requirements• Manufacturing cost reduction©Renzoku Biologics Inc.

SPEED

• Expanded opportunities for clinical
trials and commercialization ofrare diseases

16Antibody Drug Manufacturing Technology- Outline of Manufacturing Process 1. Generation of antibodyproducing cell lines
Antibody genes

2. Cultivation（Upstream Process）

CHO cells

cytoreduction

Antibodyproducing cells
CHO cells (Chinese Hamster Ovary cells)

3. Purification（Downstream Process）

Source:Pharm Tech Japan 2019, Vol.35 (No.4), 758-769(2019),
written by Mr. Akihiro Yanagita, Mr.Ryota Nakajima and Mr. Takuo Kawase©Renzoku Biologics Inc.

Culturecolumn chromatography

Drugsubstance
17

Antibody Drug Manufacturing Technology- Conventional Method (Batch) and Continuous Production
Conventional process (fed-batch culture/batch purification)
CultureHarvestOperating Process
Tank1

Purification

HarvestCapturePolish2
UF/DF

Operating Process
CultureCultureHarvestCapturePolish1
UF/DF

Continuous production process (perfusion culture/continuous purification)
CulturePurification

HarvestColumn diameter 5~10 cm(Single use)

Culture tank size 500 L(Single use）

Tank3

Purification

Column diameter 40~100 cm

Tank2

Purification

Culture tank size 2000 L x 3~6

CultureCultureSource:Pharm Tech Japan 2019, Vol.35 (No.4), 758-769(2019),
written by Mr. Akihiro Yanagita, Mr.Ryota Nakajima and Mr. Takuo Kawase

CAPEX andlower running costs©Renzoku Biologics Inc.

Small-scale factory

Highly flexible
production

FTE Reduction

Increase inproduction

Risk Reduction
18

Experienced international and interdisciplinary leadership team
Executives
Hitoshi Kuboniwa, PhD

Advisors
CEO / Representative
Director, Board Member

Edward WILLEMS, MEng, MSc

Chief Strategy/
Business Advisor

Former Senior Executive Officer, Pharmaceuticals representative,
Managing Executive Officer, General Manager of Pharmaceuticals Divisionof Chugai Pharmaceutical Co., Ltd.
More than 40 years of experience in R&D, business development,biopharmaceutical manufacturing and supply chain management in major
pharmaceutical company

Former Global Deputy Head of Capital Markets, Global Investment Bank (Crédit
Agricole)
More than 30 years of cross-border and international business experience in thefinancial sector
13 years of experience in Life Sciences venture investments, businessdevelopment, strategies, commercialization advisory

Fumiaki Yumoto, PhD

Thomas TEMPLEMAN, PhD

Chief Operating Officer

Former Project Associate Professor, Center for Structural Biology,
Institute for Materials Structure Science, KEK, High Energy Accelerator
Research Organization
More than 20 years of research experience in the U.S. (California) andJapan
Experience in supporting international business development of bioventure companies

Teruji Yoshioka

Chief Business Development
Officer, Board Member

24 years of global sales, factory management and overseas
management experience in Germany, Taiwan and China

Junichi Kataoka

Chief Technology Advisor

Former CTO, Centessa Pharmaceuticals; SVP, Nuvation Bio; SVP, Medivation(now Pfizer); VP, Hospira (now Pfizer)
More than 40 years of experience in pharmaceutical manufacturing and supply
chain, including biopharmaceuticals
13+ years in various leadership roles and obtained Six Sigma Black Belt
Certification at Johnson & Johnson

Kohei Tsumoto, PhD

Chief Science Advisor

Professor and Vice Dean, Graduate School of Engineering, The University of Tokyo
Professor, Institute of Medical Science, The University of Tokyo
International leader in physicochemical analysis of proteins, especially in the field ofantibody engineering, for more than 30 years, including former president of theProtein Science Society of Japan

Chief Finance Officer,
Board Member

More than 20 years of experience in finance, human resources,
information systems and project promotion in Singapore, ASEAN,
Europe and Japan©Renzoku Biologics Inc.

19

4. CDMO Market Entry Strategy©Renzoku Biologics Inc.

Contract biologics manufacturing is experiencing a worldwide shortage
Backlog in biologics CDMO was significant before COVID-19, and becoming much more severe

3.1xSouth Korea-based CDMO
9.3x revenue backlog

China-based CDMO
increasing revenue backlog

US-based CDMO
3.1x revenue backlog
1.7x

8.4x

9.3x

$18,470 M$ 5,100 M$ 241 M

$ 73.0 M

17.6x$16,543 M$ 144 M
$ 23.4 M
2016
Revenue$ 605 M
2016
Revenue
Backlog

2016
Revenue

2016
Revenue
Backlog

2019
Revenue$1,780 M$1,050 M
2019
Revenue
Backlog

2022
Revenue

2022
Revenue
Backlog

2022
Revenue

2022
Revenue
Backlog• Companies must pay upfront to secure a schedule, which can be a significant sum for small biotechs and academic
research institutes• Due to hundreds of ongoing clinical trials and drug launches, CDMO capacity is stretched thin despite aggressive
expansion in recent years✓ Waiting list of 12 to 24 months to start process development and manufacturing after signing contracts withmajor manufacturers
Source: Company annual reports (2017, 2019 and 2022). Deloitte 2019 Global Life Science Outlook.
©Renzoku Biologics Inc.

21

Renzoku’s Strategy : Market Perspectives

Lead time to manufacturing (months)

Renzoku targets fast contract manufacturing for small to mid-sized volumes

18

US CDMO
D
12

Japan CDMOA

Providing small to medium volumes with ashorter lead time is an underserved market,
with strong demand from innovators

6
Renzoku Biologics’ target market 3“Quick and Small”
Small Volume(< 50 kg per project)©Renzoku Biologics Inc.

US CDMOJ

S.Korea CDMOSSwiss CDMOL
US CDMOPJapan CDMOF

China CDMO
W

Medium Volume(50kg to 1000 kg per project)

Capacity(kg/year)

Large Volume(Over 1000 kg per project)

22

Renzoku’s Strategy : Technology Perspective
Depends on thecustomer whether toapply continuous
production technology
or notParadigm shift in biologics manufacturing
Fed batchIntensified Fed batch
and/or some
perfusion

Continuous hybrid

Pharmaceuticalcompanies

CDMO

CDMOs focusing onconventional technologies

Large
majority of
CDMOs

Swiss CDMO
L
Japan CDMOA

Majority of Pharmaceutical companies

Pharmaceutical companies are currently cautious about
applying continuous production
The important things for the use of continuous production
technology are:
• Platform technologization• Track record of sales approvals©Renzoku Biologics Inc.

Fully continuous
process

CDMOs active inadvanced technology

China CDMOW

US CDMOJJapan CDMOF

Limitedpharmaceuticalcompanies

The technology is expected to
evolve toward full continuous
production in the next 3-5
years.
Companies will embrace thetechnology in line with theirbusiness strategies

23

Renzoku's Expansion and Growth Strategy:
Domestic and International Expansion through a "Clone Strategy”
Deployment of small, cloneable plants through the integration of advanced production technologies• Continuous Production• Automation / Robotics• Digitalization, advanced equipment design, standardization
Domestic Factory #GMP
Clinical use- 50L

Domestic Factory

GMP
Commercial
use - 500L

Overseas Factory #GMP
Clinical use- 50L©Renzoku Biologics Inc.

GMP
Commercial
use - 500L

GMP
Clinical use
- 50L
GMP
Commercial
use - 500L
24

Continuous production facility for clinical drug manufacturing in 2026
and commercial production in 2029
Accumulate own intellectual property through process development andtechnology acquisition through open innovation
Continuous development and optimization of Renzoku Biologics’ continuous biomanufacturing process

Renzoku Biologics’ IP

50L scale facility for manufacturing clinical drugs

Commercial
Production scale(500L/nonGMP）
Clinical drug
production scale（50L/nonGMP）

Laboratory
scale（～5L）

Clinical drug
production scale(50L/GMP）

Commercial
production scale（500L/GMP）
Operation of facilities
for commercial
production

Operation of facilities
for manufacturing
clinical drugs

Operating facilities
for processdevelopment

Q1~Q2
2024

Q1~Q2
2025

Q1~Q2
2026
GMP manufacturing ofclinical drugs©Renzoku Biologics Inc.

500L scale facility for commercial production

Q4 2026~
Q1 2027

Q3~Q4
2028

Q2~Q3
2029

GMP manufacturing ofmarketed products25

5. Collaboration with SIIX Corp.
©Renzoku Biologics Inc.

EMS and CDMOs have many things in common,and collaboration will bring synergies
Focus on scalability and flexibility of
manufacturing facilities
High-specification manufacturing facility
with airflow control
Advanced Process Development andEngineering
High demands on quality control andquality assurance

EMS

Global Supply Chain Management
Serving international and domestic clients

CDMO

Manufacturing technology and software
specialized for biopharmaceuticals
Correspondence with PMDA, FDA, EMA andother regulatory authorities©Renzoku Biologics Inc.

27

EOF

Thank you for your attention
Renzoku Biologics Inc.

©Renzoku Biologics Inc.

28

Disclaimer• The information contained in this document is intended to provide financial information andperformance indicators of SIIX Corporation and Renzoku Biologics Inc. (hereinafter referred toas “the Companies”), but no representation or warranty is made regarding the content.
The document is not prepared for the purpose of soliciting investments. When actuallyinvesting, please refrain from making investment decisions based entirely on the informationon this website and make investment decisions based on your own judgment.
• The Companies have taken the utmost care with regard to the information contained in thisdocument. However, the Companies assumes no responsibility whatsoever for any errors in
the information contained herein, or for any damages resulting from the data falsification or
the data downloading by third parties.
• Some information posted on the website contains statements regarding future performance.
Such statements are not guarantees of future performance and are subject to risks anduncertainties. Please note that future performance may differ from actual results due tochanges in the environment and other factors.

©Renzoku Biologics Inc.

29